{"preliminary_commentary":{"by_channel":{"x_thread":17,"podcast":3,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02917772\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"TITAN-RCC","nct_id":"NCT02917772","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=titan-rcc-nct02917772. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TITAN-RCC","arms":[{"description":"* Induction: Mono-Therapy with Nivolumab\n* If CR/PR: Nivolumab Maintenance Mono-Therapy\n* If SD/PD: Nivolumab/Ipilimumab \"Boost 1+2\"-Combination Therapy\n* If CR/PR: Nivolumab Maintenance Mono-Therapy\n* If SD/PD: Nivolumab/Ipilimumab \"Boost 3+4\"-Combination Therapy\n* If CR/PR/SD: Nivolumab Maintenance Mono-Therapy","label":"Nivolumab/Ipilimumab","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb"],"completion_date":{"date":"2022-10","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell","Clear-cell Metastatic Renal Cell Carcinoma"],"enrollment":{"count":200,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Nivolumab/Ipilimumab","otherNames":["Opdivo/Yervoy"],"type":"BIOLOGICAL"}],"last_update":"2022-10-06","lead_sponsor":"AIO-Studien-gGmbH","official_title":"A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR)","timeFrame":"until 30 weeks after last patient first treatment, LPFT"}],"references":[{"citation":"Grimm MO, Esteban E, Barthelemy P, Schmidinger M, Busch J, Valderrama BP, Charnley N, Schmitz M, Schumacher U, Leucht K, Foller S, Baretton G, Duran I, de Velasco G, Priou F, Maroto P, Albiges L; TITAN-RCC study group. Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2023 Nov;24(11):1252-1265. doi: 10.1016/S1470-2045(23)00449-7. Epub 2023 Oct 13.","pmid":"37844597","type":"DERIVED"}],"start_date":{"date":"2016-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT02917772"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/titan-rcc-nct02917772"}